Fortress Biotech, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Fortress Biotech, Inc. (FBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.01 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2018-03-16
- Fortress Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $14.01M, a 15.48% increase from fiscal 2016.
- Fortress Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $12.13M, a 15.14% decline from fiscal 2015.
- Fortress Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2015 was $14.29M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|
| 2017-12-31 | $14.01M 10-K · filed 2018-03-16 | |
| 2016-12-31 | $12.13M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $14.29M 10-K · filed 2018-03-16 | |
| 2013-09-30 | $4.07M 10-Q · filed 2013-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |